NSD1 mutation is mainly enriched in patient group 2 (33%) compared to the other three groups (group 1: 10%, group 3: 6%, group 4: 4%), as shown in Figure 3b (p < 0.01), indicating that it may play an important role in cancer development of this subtype of tumors. Here, NSD1 is linked to cancer.